leflunomid
initi
develop
agricultur
herbicid
explor
immunosuppress
abil
inhibit
enzym
dihydroorot
dehydrogenas
potenti
leflunomid
immunosuppress
field
transplant
extens
demonstr
variou
experiment
studi
long
halflif
sever
day
pose
problem
potenti
overimmunosuppress
transplant
patient
analogu
activ
metabolit
leflunomid
develop
call
malononitrilamid
mna
also
known
best
studi
synthet
mna
much
shorter
halflif
leflunomid
hour
versu
day
believ
repres
attract
altern
leflunomid
applic
organ
transplant
leflunomid
n
prodrug
rapidli
convert
biolog
activ
metabolit
teriflunomid
chemic
serum
level
teriflunomid
refer
leflunomid
level
halflif
teriflunomid
long
human
approxim
day
drug
enter
enterohepat
recircul
excret
intestin
urinari
system
equal
proport
leflunomid
insolubl
water
suspend
carboxymethylcellulos
oral
administr
mna
design
structur
similar
oral
bioavail
substanti
affect
food
gender
effect
pharmacokinet
observ
phase
studi
leflunomid
analogu
strong
antiprolif
effect
lymphocyt
b
lymphocyt
thu
limit
format
antibodi
inhibit
pyrimidin
synthesi
import
mechan
action
leflunomid
directli
inhibit
enzym
dihydroorot
dehydrogenas
lymphocyt
reli
entir
de
novo
pathway
pyrimidin
biosynthesi
use
anoth
socal
pyrimidin
salvag
pathway
dihydroorot
dehydrogenas
inhibit
lead
deplet
nucleotid
precursor
uridin
triphosph
cytidin
triphosph
necessari
synthesi
rna
dna
henc
strongli
suppress
dna
rna
synthesi
vivo
mechan
action
leflunomid
may
depend
factor
drug
level
dispos
uridin
pool
immun
activ
pathway
involv
studi
indic
addit
inhibit
dihydroorot
dehydrogenas
leflunomid
mna
may
act
inhibit
tyrosin
kinas
phosphoryl
epiderm
growth
factor
receptor
human
fibroblast
shown
inhibit
leflunomid
shown
leflunomid
directli
inhibit
interleukin
il
protein
tyrosin
kinas
activ
associ
activ
tcell
complex
higher
concentr
also
inhibit
tyrosin
phosphoryl
janu
kinas
jak
protein
tyrosin
kinas
leflunomid
analogu
also
shown
possess
strong
inhibitori
activ
antiapoptot
tyrosin
kinas
bruton
tyrosin
kinas
key
factor
tcellindepend
antibodi
format
hypothesi
leflunomid
may
exhibit
one
mechan
action
vivo
illustr
mice
uridin
restor
prolifer
igm
product
lipopolysaccharidestimul
b
cell
wherea
suppress
igg
product
revers
phenomenon
correl
dosedepend
manner
tyrosin
phosphoryl
protein
known
involv
signal
transduct
pathway
doubl
vivo
mechan
action
confirm
rat
xenoreact
counteract
administr
uridin
wherea
alloreact
also
inhibit
variou
macrophag
function
leflunomid
mna
describ
particular
inhibit
product
oxygen
radic
inhibit
igemedi
hypersensit
respons
express
receptor
type
well
tumor
necrosi
factor
tnf
mediat
nuclear
factor
kappa
b
activ
tacrolimu
also
inhibit
matur
dendrit
cell
prevent
upregul
activ
marker
product
phenomenon
revers
exogen
uridin
equival
stronger
immunosuppress
activ
leflunomid
vitro
vivo
immunosuppress
effect
synergist
calcineurin
inhibitor
cni
mycophenol
mofetil
mmf
interestingli
leflunomid
shown
possess
antivir
effect
although
precis
mechan
unclear
inhibit
viral
replic
member
herpesviru
famili
prevent
tegument
acquisit
viral
nucleocapsid
late
stage
virion
assembl
implic
leflunomid
effect
multidrugresist
cytomegaloviru
cmv
vitro
although
vitro
activ
modest
select
index
low
anticmv
effect
leflunomid
confirm
rat
model
heterotop
heart
transplant
anoth
interest
featur
leflunomid
vasculoprotect
effect
independ
inhibit
dihydroorot
dehydrogenas
variou
rodent
transplant
studi
leflunomid
shown
least
equal
potent
cyclosporin
abl
synerg
cyclosporin
induc
toler
specif
characterist
leflunomidemedi
immunosuppress
rat
abil
interrupt
ongo
acut
reject
efficaci
prevent
treat
chronic
vascular
reject
one
attract
characterist
leflunomid
mna
strong
capac
delay
xenograft
reject
induc
partial
xenograft
toler
may
relat
strong
suppress
effect
leflunomid
tcellindepend
xenoantibodi
format
capac
induc
natur
killer
cell
nonrespons
modul
xenoantigen
express
monotherapi
rat
combin
microemulsifi
cyclosporin
dog
tacrolimu
nonhuman
primat
reduc
chronic
allograft
nephropathi
significantli
prolong
renal
allograft
surviv
main
role
leflunomid
renal
transplant
nowaday
treatment
bk
viru
nephropathi
bkvn
base
vitro
effect
antibk
concentr
vivo
target
level
mgml
propos
prospect
studi
renal
transplant
recipi
biopsyproven
bkvn
treat
leflunomid
combin
discontinu
mmf
reduct
tacrolimu
ng
ml
rang
although
leflunomid
level
lower
rang
averag
mgml
signific
reduct
serum
urin
bkv
titer
obtain
allograft
function
stabil
overal
graft
loss
rate
bkv
less
encourag
result
obtain
anoth
prospect
openlabel
studi
viral
clearanc
obtain
patient
signific
toxic
result
discontinu
drug
patient
contribut
reduct
immunosuppress
agent
leflunomid
efficaci
bkvn
treatment
unclear
moment
base
recent
vitro
data
suggest
combin
sirolimu
leflunomid
might
effect
treatment
approach
also
studi
context
bkvn
although
abl
decreas
bk
viral
load
treatment
associ
acut
reject
decreas
renal
function
advers
event
compar
reduct
immunosuppress
anim
studi
leflunomid
abl
revers
acut
chronic
reject
two
clinic
studi
report
leflunomid
capabl
stabil
allograft
function
patient
worsen
allograft
function
due
chronic
allograft
dysfunct
phase
ii
multicent
studi
perform
involv
renal
transplant
patient
combin
tacrolimu
corticosteroid
patient
receiv
experienc
reduc
number
acut
reject
effect
graft
surviv
week
reduct
acut
reject
episod
pronounc
subgroup
target
level
obtain
second
week
note
mean
total
lowdens
lipoprotein
cholesterol
level
lower
group
versu
placebo
group
valid
result
hamper
design
studi
time
develop
field
organ
transplant
ceas
although
rat
toler
leflunomid
well
dog
readili
develop
anemia
gastrointestin
ulcer
reportedli
frequent
side
effect
arthriti
patient
receiv
longterm
leflunomid
treatment
diarrhea
nausea
alopecia
rash
lead
dropout
rate
recent
thrombot
microangiopathi
attribut
leflunomid
report
patient
treat
bkvn
abovement
phase
ii
studi
involv
dosedepend
increas
side
effect
includ
anemia
hypokalemia
symptomat
myocardi
ischemia
esophag
report
side
effect
pneumon
peripher
neuropathi
leflunomid
teratogen
effect
anim
human
washout
period
cholestyramin
advis
women
men
consid
concept
combin
leflunomid
methotrex
might
increas
risk
bone
marrow
suppress
liver
toxic
furthermor
rifampin
acceler
convers
leflunomid
teriflunomid
might
increas
level
combin
warfarin
potenti
increas
intern
normal
ratio
role
leflunomid
renal
transplant
limit
treatment
patient
bkvn
promis
result
report
respect
mna
shorter
halflif
consid
promis
class
immunosuppress
result
random
clinic
trial
disappoint
develop
agent
organ
transplant
halt
chemic
structur
pharmacolog
ethyl
hydrochlorid
synthet
structur
analogu
myriocin
metabolit
ascomycet
isaria
sinclairii
type
veget
wasp
maxim
concentr
area
curv
proport
dose
indic
pharmacokinet
profil
linear
volum
distribut
larg
superior
blood
volum
indic
widespread
tissu
penetr
undergo
hepat
metabol
long
halflif
around
hour
uniqu
mechan
action
mainli
affect
lymphocyt
traffick
act
highaffin
agonist
sphingosin
bind
receptor
result
intern
render
lymphocyt
unabl
respond
natur
occur
gradient
low
concentr
thymu
secondari
lymphoid
organ
high
concentr
lymph
plasma
retain
lymphocyt
environ
lymphoid
organ
follow
administr
mice
b
cell
immedi
leav
peripher
blood
migrat
peripher
lymph
node
mesenter
lymph
node
peyer
patch
cell
return
peripher
blood
withdraw
drug
without
undergo
apoptot
death
alter
cell
traffick
accompani
reduct
lymphocyt
infiltr
graft
organ
interestingli
lymphocyt
treat
ex
vivo
reintroduc
vivo
similarli
migrat
peripher
lymphoid
tissu
indic
act
directli
lymphocyt
process
acceler
home
complet
block
vivo
coadministr
monoclon
antibodi
vitro
presenc
increas
express
certain
intercellular
adhes
molecul
human
endotheli
cell
thu
alter
cell
traffick
may
result
direct
action
lymphocyt
also
effect
endotheli
cell
interestingli
suggest
regulatori
cell
differ
affect
compar
teffector
cell
regulatori
cell
express
lower
level
receptor
henc
show
reduc
respons
furthermor
vitro
tregulatori
cell
possess
increas
suppress
activ
antigenspecif
prolifer
assay
unlik
cni
poor
inhibitor
tcell
function
vitro
particular
influenc
antigeninduc
product
vitro
exposur
high
concentr
induc
chromatin
condens
typic
dna
fragment
format
apoptot
bodi
whether
administr
vivo
also
associ
signific
apoptosi
matter
debat
also
present
murin
dendrit
cell
upon
administr
dendrit
cell
lymph
node
spleen
reduc
express
downregul
transendotheli
migrat
diminish
recent
studi
demonstr
inhibit
lymphangiogenesi
thu
prolong
allogen
islet
surviv
mice
experiment
experi
given
daili
oral
gavag
mark
antireject
properti
mice
rat
dog
monkey
mgkg
prolong
surviv
skin
allograft
highli
allogen
rodent
model
da
lew
rat
combin
short
cours
peritranspl
oral
mgkg
day
prolong
cardiac
allograft
surviv
effici
posttranspl
treatment
tacrolimu
mgkg
cardiac
liver
allograft
surviv
prolong
aci
lew
rat
model
either
induct
mainten
treatment
even
delay
administr
interrupt
ongo
allograft
reject
suggest
role
rescu
agent
block
reject
also
graftversushost
diseas
rat
intestin
transplant
may
also
protect
form
ischemiareperfus
injuri
partial
cytoprotect
action
smalland
largeanim
model
provid
evid
act
synergi
cni
benefit
result
pharmacokinet
interact
induct
cours
act
synergi
posttranspl
tacrolimu
prolong
cardiac
allograft
surviv
rat
similar
phenomenon
observ
use
posttranspl
combin
cyclosporin
rat
skin
heart
allograft
show
synergist
effect
cni
heart
liver
transplant
aci
lew
rat
model
show
synergi
cyclosporin
dog
kidney
mgkgday
monkey
kidney
mgkgday
transplant
final
mgkg
synerg
cni
dog
liver
transplant
synergi
rapamycin
also
observ
rat
cardiac
transplant
benzyloxyphenylthio
ethyl
hydrochlorid
similar
molecular
structur
alon
combin
lowdos
cyclosporin
mmf
prolong
skin
heart
renal
allograft
surviv
stabl
renal
transplant
patient
maintain
cyclosporin
toler
well
one
oral
dose
mg
similarli
effect
anim
singl
dose
caus
lymphopenia
dosedepend
intens
durat
equal
affect
cell
cell
memori
cell
cell
b
cell
phase
ii
iii
studi
de
novo
renal
transplant
shown
mg
combin
fulldos
cyclosporin
steroid
effect
mmf
combin
fulldos
cyclosporin
steroid
although
patient
lower
creatinin
clearanc
month
mg
allow
reduct
cyclosporin
exposur
mg
combin
reduceddos
cyclosporin
result
underimmunosuppress
also
combin
tacrolimu
mg
superior
mmf
recent
studi
de
novo
renal
transplant
recipi
recent
report
combin
everolimu
benefici
regard
prevent
acut
reject
preserv
allograft
function
renal
transplant
recipi
high
risk
delay
graft
function
side
effect
gener
similar
immunosuppress
hypertens
anemia
constip
nausea
commonli
report
side
effect
specif
bradycardia
macularretin
edema
dyspnea
transient
rise
liver
function
test
although
consid
main
impedi
clinic
develop
reduct
heart
rate
first
dose
transient
persist
mainten
phase
importantli
typic
side
effect
cni
nephrotox
neurotox
diabetogen
observ
uniqu
mechan
action
avail
clinic
studi
show
superior
standard
care
therefor
futur
organ
transplant
uncertain
chemic
structur
pharmacolog
oh
new
synthet
structur
analogu
promis
immunomodul
effect
autoimmun
transplant
immunolog
besid
wellknown
role
miner
bone
homeostasi
nonclass
effect
vitamin
increasingli
recogn
modul
growth
differenti
function
variou
cell
type
regul
immun
respons
cardiovascular
process
cancer
prevent
local
vitamin
metabol
allow
immun
cell
modul
immun
respons
autonom
optim
immun
function
autocrin
andor
paracrin
circuit
crucial
depend
avail
circul
oh
exact
level
circul
oh
need
meet
requir
vitamin
suffici
still
matter
debat
especi
light
nonclass
effect
vitamin
role
oh
immun
regul
suggest
presenc
receptor
vitamin
receptor
vdr
almost
immun
cell
includ
activ
cell
b
cell
neutrophil
antigenpres
cell
henc
modul
innat
adapt
immun
respons
moreov
vdr
express
immun
cell
control
immun
signal
furthermor
immun
cell
express
vitamin
metabol
enzym
b
lymphocyt
dendrit
cell
allow
local
convers
oh
oh
repres
import
mechan
immun
cell
reach
supraphysiolog
level
oh
need
influenc
immun
respons
without
affect
system
level
oh
furthermor
express
immun
cell
control
immun
signal
exampl
express
monocytesmacrophag
upregul
lipopolysaccharid
mycobacterium
tuberculosisderiv
kda
lipoprotein
viral
infect
moreov
express
macrophag
dendrit
cell
suppress
oh
allow
massiv
local
product
oh
macrophag
patient
granulomat
diseas
altern
negativefeedback
loop
oh
upregul
immun
cell
upon
exposur
oh
monocyt
acquir
phenotyp
featur
macrophag
macrophag
obtain
increas
chemotact
phagocyt
activ
moreov
tolllik
receptor
activ
monocyt
macrophag
result
upregul
vdr
vdr
target
gene
lead
induct
cathelicidin
antimicrobi
peptid
kill
mycobacterium
tuberculosi
oh
inhibit
dendrit
cell
matur
decreas
level
major
histocompat
complex
class
ii
costimulatori
molecul
enhanc
endocyt
capac
inhibit
product
enhanc
releas
macrophag
inflammatori
dendrit
cell
therebi
deviat
toward
immatur
tolerogen
phenotyp
vitro
well
vivo
capac
induc
develop
regulatori
cell
upon
tcell
activ
vdr
express
dramat
increas
furthermor
oh
also
directli
alter
cytokin
profil
cell
inhibit
product
inflammatori
well
cytokin
high
low
regulatori
cell
induc
vitamin
exposur
select
induc
within
cell
molecular
pathway
oh
modul
express
gene
immun
system
vari
wide
review
refer
next
classic
interact
vdrspecif
bind
site
promot
region
target
gene
vitamin
drespons
element
inhibit
oh
also
interfer
pathway
transcript
regul
exampl
oh
mediat
inhibit
due
impair
nuclear
factor
activ
cellsactiv
complex
format
subsequ
associ
bind
site
within
promot
expos
b
cell
oh
inhibit
prolifer
plasma
cell
differenti
immunoglobulin
secret
igg
igm
memori
bcell
gener
induc
bcell
apoptosi
final
oh
put
forward
import
regul
lymphocyt
traffick
activ
oh
imprint
activ
cell
termin
differenti
b
cell
skinhom
properti
via
induct
skinhom
receptor
fact
oh
analogu
influenc
immun
system
immunomodul
induct
immun
shift
regul
cell
make
product
appeal
clinic
use
especi
treatment
prevent
autoimmun
diseas
nod
mous
upregul
regul
cell
shift
away
toward
could
observ
oh
treat
mice
local
pancrea
well
peripher
immun
system
moreov
restor
defect
sensit
apoptosi
characterist
nod
lymphocyt
observ
result
better
elimin
autoreact
effector
cell
increas
sensit
apoptosi
describ
differ
apoptosisinduc
signal
mechan
may
explain
earli
shortterm
oh
treatment
clinic
onset
autoimmun
lead
longterm
protect
restor
selftoler
clear
addit
even
synergist
effect
observ
oh
analogu
classic
immunosuppress
cyclosporin
sirolimu
mmf
vitro
sever
vivo
autoimmun
diseas
model
autoimmun
diabet
experiment
autoimmun
encephalomyel
moreov
oh
analogu
investig
variou
transplant
model
pancreat
islet
alloand
xenotransplant
mice
allogen
heart
skin
transplant
mice
allogen
aorta
bone
marrow
heart
kidney
liver
transplant
rat
overal
conclus
drawn
studi
monotherapi
oh
analogu
provok
modest
prolong
graft
function
surpris
view
rather
weak
intrins
effect
oh
analogu
cell
howev
conjunct
immunosuppress
strong
synergist
effect
often
observ
addit
view
effect
antigen
present
direct
immun
system
direct
oh
may
help
induc
toler
multipl
group
report
correl
vitamin
defici
suscept
respiratori
infect
especi
context
infect
mycobacterium
tuberculosi
gramneg
bacteria
autier
gandini
perform
metaanalysi
includ
independ
random
control
trial
demonstr
administr
vitamin
supplement
associ
decreas
overal
mortal
rate
rel
risk
confid
interv
still
lack
nonbias
larg
cohort
studi
sustain
propos
benefit
vitamin
supplement
optim
immun
function
mutat
gene
well
gene
impair
enzymat
activ
describ
polymorph
gene
propos
associ
type
diabet
mellitu
suscept
analogu
vitamin
could
success
block
progress
insul
prediabet
nod
mice
along
prevent
recurr
autoimmun
diabet
nod
mice
syngen
islet
transplant
combin
immunomodul
agent
major
concern
remain
side
effect
oh
calcium
bone
metabol
use
oh
analogu
maintain
amplifi
immunomodulatori
effect
combin
reduc
effect
calcium
bone
partial
conquer
problem
addit
use
calciumlow
condit
limit
nutrient
calcium
intak
bone
resorpt
inhibitor
bisphosphon
aid
bypass
neg
side
effect
hypercalcemia
excess
bone
resorpt
therebi
facilit
step
toward
clinic
applic
oh
analogu
potent
immunomodulatori
properti
discoveri
vdr
vitamin
dmetabol
enzym
immun
cell
evid
oh
exert
plethora
effect
target
innat
adapt
immun
compart
emerg
data
link
inadequ
vitamin
level
immun
anomali
increas
infect
rate
autoimmun
interest
context
vdr
agonist
especi
hypocalcem
vitamin
analogu
plausibl
candid
prevent
andor
treatment
infect
tuberculosi
sever
autoimmun
disord
bredinin
nucleosid
analogu
structur
similar
ribavirin
first
isol
cultur
media
ascomycet
eupenicillium
brefeldianum
harvest
soil
hachijo
island
japan
weak
antibiot
activ
candida
albican
bredinin
exert
immunosuppress
function
select
inhibit
enzym
inosin
monophosph
dehydrogenas
guanosin
monophosph
synthetas
requir
gener
guanosin
monophosph
inosin
monophosph
de
novo
pathway
contrast
azathioprin
bredinin
incorpor
nucleic
acid
cell
result
fewer
side
effect
myelosuppress
hepatox
bredinin
found
inhibit
humor
cellular
immun
select
inhibit
lymphocyt
prolifer
canin
model
renal
transplant
bredinin
prolong
graft
surviv
human
compar
azathioprin
bredinin
show
equal
potent
immunosuppress
activ
fewer
advers
effect
expect
base
similar
structur
ribavirin
bredinin
exhibit
vitro
antivir
activ
cmv
respiratori
syncyti
viru
measl
hepat
c
corona
viru
parainfluenza
influenza
viru
recent
studi
bredinin
substitut
mmf
patient
bkv
urin
bkv
dna
urin
becam
neg
five
seven
patient
remain
two
patient
signific
decreas
urinari
bkv
dna
acut
reject
deterior
graft
function
occur
studi
period
princip
advers
reaction
associ
use
bredinin
leukopenia
abnorm
hepat
function
rash
increas
level
uric
acid
vomit
bredinin
mainli
use
japan
infrequ
use
elsewher
consequ
experi
bredinin
limit
result
show
safe
effect
immunosuppress
human
kidney
transplant
antivir
activ
bredinin
might
yet
anoth
drug
evalu
set
bkvn
multipl
potenti
candid
compound
one
enter
clinic
trial
atp
congen
cp
tasocitinib
tofacitinib
pfizer
nj
bind
atp
catalyt
site
jak
molecul
propos
analysi
cellular
level
could
adequ
mean
monitor
immunomodulatori
effect
tyrosin
kinas
essenti
signal
transduct
common
gammachain
cytokin
receptor
nucleu
express
receptor
restrict
immun
cell
make
attract
target
new
immunosuppress
signal
transduct
mediat
obligatori
lymphocyt
activ
differenti
homeostasi
evidenc
find
defici
result
sever
combin
defici
syndrom
possibl
detriment
effect
interfer
signal
relat
fact
toler
induct
essenti
depend
pathway
thu
challeng
immunosuppress
drug
design
achiev
select
inhibit
versu
activ
although
pfizer
claim
select
use
vitro
assay
clinic
data
suggest
ratio
far
less
narrow
select
confirm
work
karaman
et
al
potent
inhibitori
potenc
select
inhibitor
develop
date
rodent
nonhuman
primat
exert
strong
suppress
immun
reaction
prolong
surviv
cardiac
renal
allograft
monotherapi
significantli
delay
onset
reject
kidney
allograft
nonhuman
primat
significantli
reduc
product
express
cell
furthermor
inhibit
cellular
alloimmun
respons
vitro
administr
vivo
result
reduct
nk
cell
tcell
number
wherea
effector
memori
tcell
level
unalt
recent
shown
select
inhibit
tcell
effector
function
preserv
suppress
activ
high
regulatori
cell
evalu
induct
mainten
therapi
phase
iia
multicent
openlabel
random
control
trial
kidney
transplant
recipi
patient
receiv
induct
therapi
mmf
steroid
patient
group
receiv
tacrolimu
patient
group
administ
mg
mg
twice
day
respect
high
incid
bkvn
group
protocol
adjust
stop
mmf
decreas
steroid
exposur
compar
tacrolimu
group
show
similar
rate
acut
reject
episod
allograft
function
experienc
greater
incid
hyperlipidemia
infect
suggest
addit
inhibit
phase
iib
trial
compar
cyclosporin
standard
dosag
versu
mg
twice
day
month
mg
twice
day
mg
twice
day
month
mg
twice
day
patient
receiv
addit
induct
therapi
mmf
steroid
unexpectedli
lower
dosag
arm
show
trend
toward
lowest
reject
rate
superior
allograft
function
howev
studi
import
advers
event
includ
increas
cmv
infect
rate
bkvn
arm
data
present
american
transplant
congress
dose
escal
studi
frequent
advers
event
infect
gastrointestin
side
effect
mg
mg
twice
day
associ
mean
decreas
hemoglobin
baselin
addit
decreas
natur
killer
cell
b
cell
chang
number
neutrophil
total
lymphocyt
platelet
cell
summari
combin
mmf
result
accept
rate
acut
reject
evid
overimmunosuppress
mg
twice
day
combin
mmf
mg
twice
day
coadminist
mmf
result
similar
outcom
associ
modest
lipid
elev
higher
rate
viral
infect
opinion
consid
known
sideeffect
profil
cni
evalu
warrant
given
side
effect
report
use
challeng
remain
develop
immunosuppress
drug
truli
select
inhibit
versu
activ
lack
success
develop
select
antagonist
probabl
relat
focu
chemic
analogu
atp
success
expect
develop
molecul
display
alloster
inhibit
via
bind
noncatalyt
site
sotrastaurin
lowmolecularweight
synthet
compound
potent
revers
inhibit
isoform
protein
kinas
c
pkc
importantli
lesser
activ
sotrastaurin
primarili
metabol
hepat
inact
metabolit
ndesmethylsotrastaurin
similar
potenc
sotrastaurin
present
low
blood
concentr
less
parent
exposur
renal
excret
sotrastaurin
neglig
small
amount
excret
bile
dose
elimin
halflif
sotrastaurin
averag
hour
clinic
trial
recommend
patient
administ
sotrastaurin
consist
either
without
food
avoid
foodrel
fluctuat
drug
exposur
time
clinic
drug
interact
studi
date
demonstr
sotrastaurin
increas
area
concentrationtim
curv
everolimu
tacrolimu
sotrastaurin
increas
tacrolimu
concentr
inasmuch
tacrolimu
dose
need
achiev
given
c
lower
combin
sotrastaurin
versu
mmf
convers
sotrastaurin
area
concentrationtim
curv
increas
cyclosporin
ketoconazol
pkc
famili
serinethreoninespecif
protein
kinas
involv
divers
signal
transduct
pathway
modul
whole
rang
cellular
process
includ
activ
prolifer
differenti
apoptosi
autophagi
shown
essenti
tcell
signal
transduct
pathway
modul
respons
includ
product
control
bcell
receptorinduc
transactiv
tindepend
bcell
respons
final
influenc
macrophag
function
note
sotrastaurin
demonstr
nontox
ad
human
islet
cultur
result
suggest
appropri
immunosuppress
candid
clinic
trial
islet
transplant
recent
shown
nonhuman
primat
sotrastaurin
combin
cyclosporin
subtherapeut
dose
result
markedli
prolong
renal
allograft
surviv
indic
synergist
immunosuppress
effect
phase
ii
random
control
trial
sotrastaurin
standard
reduc
tacrolimu
compar
standard
tacrolimu
alon
addit
induct
therapi
steroid
three
month
posttranspl
stabl
patient
sotrastaurin
switch
tacrolimu
mmf
three
arm
show
equal
efficaci
month
end
studi
differ
allograft
function
although
incid
acut
reject
significantli
higher
standard
tacrolimu
sotrastaurin
arm
lack
efficaci
studi
prematur
discontinu
anoth
recent
trial
de
novo
renal
transplant
recipi
immedi
graft
function
studi
subject
random
sotrastaurin
tacrolimu
patient
receiv
basiliximab
mmf
steroid
studi
demonstr
lower
degre
efficaci
better
renal
function
cnifre
regimen
sotrastaurin
mmf
versu
tacrolimusbas
control
studi
combin
sotrastaurin
everolimu
current
ongo
abovement
clinic
trial
incid
tachycardia
seriou
infect
dosedepend
chronotrop
effect
observ
preclin
phase
sotrastaurin
studi
therefor
higher
heart
rate
tachycardia
observ
sotrastaurin
combin
mmf
unexpect
tachycardia
advers
event
mild
major
occur
soon
transplant
sotrastaurin
block
pkcmediat
earli
tcell
activ
provid
new
approach
immunosuppress
distinct
cni
howev
efficaci
result
phase
ii
studi
support
combin
sotrastaurin
mg
twice
day
mmf
cnifre
regimen
base
result
recent
report
bigaud
et
al
nonhuman
primat
sotrastaurin
cnispar
agent
warrant
evalu
futur
clinic
trial
bortezomib
proteasom
inhibitor
approv
food
drug
administr
treatment
multipl
myeloma
bortezomib
increasingli
use
set
solidorgan
transplant
bortezomib
administ
four
dose
mgm
intraven
infus
period
kidney
transplant
recipi
prior
bortezomib
administr
patient
need
premed
methylprednisolon
peak
serum
concentr
reach
minut
drug
clear
within
hour
bortezomib
select
inhibitor
proteasom
prevent
activ
induc
apoptosi
rapidli
divid
metabol
activ
cell
extens
protein
synthesi
abil
bortezomib
target
plasma
cell
spur
interest
new
therapeut
approach
treatment
prevent
alloantibodi
format
organ
transplant
vitro
bortezomib
associ
reduct
number
bone
marrowderiv
plasma
cell
attenu
alloantibodi
product
bortezomib
primarili
act
plasma
cell
deplet
result
reduc
antibodi
product
tdepend
antigen
margin
zone
b
cell
resist
bortezomibmedi
effect
tindepend
type
respons
less
affect
mous
model
lupu
bortezomib
deplet
shortand
longliv
plasma
cell
result
reduct
antidoublestrand
dna
antibodi
product
vogelbach
et
al
recent
establish
bortezomib
alon
combin
sirolimu
also
prevent
alloantibodi
format
rat
model
kidney
transplant
bortezomib
therapi
antibodymedi
reject
result
mix
result
everli
et
al
administ
bortezomib
patient
antibodymedi
reject
concomit
acut
cellular
reject
refractori
current
avail
therapi
bortezomib
administr
result
resolut
antibodymedi
reject
patient
decreas
donorspecif
antibodi
level
improv
allograft
function
anoth
studi
walsh
et
al
report
result
bortezomib
treatment
patient
antibodymedi
reject
bortezomib
treatment
associ
variabl
result
better
respons
earli
occur
first
month
transplant
versu
late
occur
month
transplant
antibodymedi
reject
contrast
studi
sberrosoussan
et
al
bortezomib
treatment
result
decreas
donorspecif
antibodi
mean
fluoresc
intens
use
sole
desensit
therapi
four
renal
transplant
recipi
subacut
antibodymedi
reject
persist
donorspecif
antibodi
howev
studi
bortezomib
therapi
initi
week
month
follow
diagnosi
antibodymedi
reject
repeat
biopsi
perform
follow
bortezomib
treatment
common
side
effect
associ
bortezomib
treatment
gastrointestin
toxic
thrombocytopenia
neuropathi
potenti
sever
disabl
date
increas
rate
opportunist
infect
report
importantli
although
bortezomib
associ
substanti
reduct
donorspecif
antibodi
level
result
decreas
protect
antibodi
level
proteasom
inhibitor
therapi
potenti
treatment
antibodymedi
reject
kidney
transplant
recipi
primari
rescu
therapi
optim
respons
bortezomib
obtain
antibodymedi
reject
occur
earli
posttranspl
bortezomib
treatment
initi
promptli
bortezomib
recent
also
shown
provid
effect
therapi
antibodymedi
reject
heart
lung
transplant
recipi
other
cladiribin
adenosin
deaminaseresist
analogu
deoxyadenosin
use
treatment
leukemia
lymphoma
number
studi
explor
immunosuppress
capac
cladiribin
vitro
cladribin
inhibit
band
tcell
prolifer
vivo
cladiribin
monotherapi
shown
prolong
skin
allograft
surviv
mice
combin
cyclosporin
prolong
liver
heart
allograft
surviv
rat
effect
cyclosporin
monotherapi
smallbowel
allograft
howev
clinic
trial
publish
date
farnesyltransferas
inhibitor
develop
anticanc
compound
inhibit
ra
gtpase
inhibit
lectininduc
prolifer
antigenpres
cellinduc
tcell
prolifer
compound
also
inhibit
lymphocyt
cytokin
product
promot
apoptosi
lectinactiv
lymphocyt
anoth
farnesyltransferas
inhibitor
shown
vitro
block
secret
cell
suppress
alloreact
rat
heterotop
cardiac
transplant
model
alon
combin
subtherapeut
dose
cyclosporin
delay
develop
acut
reject
given
combin
antireject
antioncogen
effect
farnesyltransferas
inhibitor
could
repres
attract
new
class
immunosuppress
malignancypron
organ
transplant
recipi
futur
clinic
trial
confirm
efficaci
tcell
receptor
recogn
specif
antigen
lymphoid
cellspecif
kinas
lck
phosphoryl
togeth
receptorassoci
complex
phosphoryl
zincassoci
phosphorylas
event
trigger
downstream
cascad
increas
intracellular
calcium
activ
calcineurin
inhibitor
lck
becom
avail
recent
structur
similar
molecul
shown
prolong
surviv
heterotop
murin
heart
renal
subcapsular
islet
graft
well
blunt
product
immunoglobulin
emodin
c
h
cyclic
deriv
rhubarb
root
rhizom
shown
prolong
murin
skin
graft
surviv
dampen
product
howev
neither
archetyp
compound
show
suffici
specif
lck
versu
kinas
warrant
clinic
develop
fr
immunosuppress
agent
isol
cultur
pseudomona
fluorescen
inhibit
transcript
activ
act
predominantli
antigenpres
cell
fr
demonstr
synergi
tacrolimu
vitro
vivo
murin
model
skin
transplant
compar
optim
dose
tacrolimu
alon
combin
fr
tacrolimu
prolong
graft
surviv
brequinar
sodium
exert
immunosuppress
effect
inhibit
enzym
dihydroorot
dehydrogenas
result
inhibit
b
lymphocyt
although
characterist
brequinar
suggest
would
attract
immunosuppress
suboptim
pharmacolog
profil
jeopard
use
transplant
patient
futur
use
drug
field
transplant
requir
develop
analogu
exhibit
shorter
halflif
reduc
toxic
spergualin
origin
isol
cultur
filtrat
bacillu
laterosporu
explor
new
anticanc
antibiot
substanc
analogu
subsequ
becam
wide
known
promis
new
immunosuppress
precis
mode
action
larg
unknown
poor
oral
bioavail
must
deliv
parenter
hamper
widespread
clinic
use
efficaci
demonstr
treatment
kidney
allograft
reject
aboincompat
kidney
transplant
transplant
sensit
patient
analogu
develop
allow
oral
administr
major
clinic
indic
limit
treatment
reject
crise
may
interest
altern
steroid
antilymphocyt
agent
fact
remain
effect
recurr
administr
promis
upon
cellular
uptak
cyclophosphamid
extens
metabol
activ
compound
phosphoramid
mustard
acrolein
reaction
phosphoramid
mustard
dna
result
cell
death
limit
efficaci
multipl
side
effect
standard
indic
cyclophosphamid
transplant
today
desensit
highli
sensit
recipi
prior
kidney
transplant
protocol
involv
repeat
plasmapheresi
combin
cyclophosphamid
either
without
continu
steroid
kidney
transplant
becom
avail
sever
decad
total
lymphoid
irradi
tli
use
treatment
hodgkin
diseas
possibl
appli
tli
immunosuppress
regimen
rather
anticanc
treatment
discov
investig
stanford
univers
procedur
tli
deliv
two
port
first
socal
mantl
port
includ
lymph
node
neck
axilla
mediastinum
port
call
invert
encompass
aortic
iliac
pelvic
lymph
node
spleen
usual
total
dose
gy
gy
rad
administ
daili
fraction
gy
much
current
avail
experiment
evid
immunolog
mechan
underli
tliinduc
toler
point
import
suppressor
cell
group
strober
identifi
posttli
suppressor
cell
hosttyp
natur
killer
cell
protect
effect
tli
graftversushost
diseas
abrog
mice
inactiv
gene
hosttyp
natur
killer
cell
produc
stimul
donortyp
cell
produc
also
definit
evid
function
import
activ
suppressor
cell
deliv
demonstr
could
prevent
graftversushost
diseas
vivo
posttli
attenu
effector
tlymphocyt
reactiv
equal
propos
respons
observ
immunosuppress
state
tli
intrins
tcell
defect
depend
irradi
thymu
extrathym
tissu
tli
anerg
cell
shown
incap
prolifer
even
presenc
exogen
studi
tli
shown
lead
thymic
clonal
delet
donoror
hostreact
lymphocyt
tlitreat
mice
also
exhibit
decreas
antidonor
cytotox
tcell
precursor
frequenc
final
strober
group
show
lymphocyt
recov
soon
tli
wherea
lymphocyt
remain
defici
sever
month
show
defect
also
prevent
thymic
shield
irradi
domin
tli
confirm
group
rodent
larg
anim
recent
nador
et
al
demonstr
toler
induct
condit
tli
antithymocyt
globulin
atg
depend
upon
abil
natur
occur
regulatori
natur
killer
cell
regulatori
cell
suppress
residu
alloreact
cell
capabl
reject
allograft
tlitreat
balbc
mice
receiv
fulli
allogen
bone
marrow
skin
graft
first
day
tli
becam
stabl
hematopoiet
chimera
without
sign
graftversushost
diseas
develop
perman
donorspecif
toler
preserv
antithirdparti
reactiv
toler
induct
critic
depend
width
irradi
field
time
transplant
tli
total
dose
tli
absenc
presensit
although
bone
marrow
chimer
could
easili
induc
toler
either
heart
kidney
allograft
obtain
suggest
tliinduc
bone
marrow
chimer
necessarili
creat
toler
toward
organspecif
antigen
combin
tli
lowdos
cyclosporin
found
effect
clinic
safe
rat
tli
postop
atg
induc
perman
specif
transplant
toler
toward
heart
allograft
transplant
dog
encourag
result
led
similar
trial
clinic
kidney
transplant
myburgh
et
al
appli
modifi
tli
regimen
baboon
low
dosag
widefield
exposur
show
toler
achiev
larger
anim
without
concomit
bone
marrow
transplant
also
heart
heartlung
transplant
experi
xenogen
nonhuman
primat
speci
preoper
tli
administ
combin
cyclosporin
atg
cyclosporin
splenectomi
cyclosporin
medrol
effici
treatment
regimen
pretranspl
tli
combin
cyclosporin
methotrex
pig
heartintobaboon
model
result
graft
surviv
time
week
regimen
abl
inhibit
xenoreact
natur
antibodi
product
xenoreact
macrophag
pig
isletintorat
xenograft
model
tli
combin
deoxyspergualin
extrem
effect
even
discord
lambintopig
model
tli
synerg
cyclosporin
azathioprin
provok
increas
mean
xenograft
surviv
time
princip
disadvantag
clinic
applic
tli
complet
regimen
fraction
daili
irradi
need
administ
complet
suffici
close
moment
transplant
find
suitabl
donor
organ
within
restrict
timefram
problemat
investig
therefor
explor
possibl
use
tli
transplant
mous
rat
heart
allograft
model
posttranspl
tli
significantli
prolong
graft
surviv
combin
monoclon
antibodi
infus
donortyp
dendrit
cell
precursor
first
clinic
kidney
transplant
util
tli
perform
univers
minnesota
patient
previous
reject
renal
allograft
similar
result
increas
graft
surviv
compar
histor
control
data
achiev
patient
popul
use
cyclosporin
eas
administr
investig
conclud
prefer
cyclosporin
tli
control
trial
perform
univers
leuven
endstag
diabet
nephropathi
patient
receiv
cadaver
kidney
allograft
investig
effect
pretranspl
tli
daili
fraction
gy
follow
weekli
tli
dose
suitabl
donor
found
follow
lowdos
posttranspl
prednison
mainten
treatment
longterm
followup
reveal
reject
episod
frequent
patient
graft
surviv
significantli
inferior
tlitreat
group
excess
mortal
tlitreat
patient
due
sepsi
result
highdos
steroid
therapi
need
treat
reject
crise
clinic
experi
confirm
anim
data
also
show
tli
insuffici
provok
longterm
graft
surviv
toler
extra
manipul
need
studi
stanford
univers
patient
receiv
first
one
patient
second
cadaver
renal
allograft
use
tli
atg
actuari
graft
surviv
year
respect
ten
patient
never
reject
crisi
despit
overal
poor
hlamatch
donor
recipi
followup
studi
specif
antidonor
mix
lymphocyt
cultur
hypoor
nonrespons
demonstr
patient
immunosuppress
drug
could
withdrawn
evalu
larger
group
patient
treat
protocol
center
show
graft
surviv
less
cyclosporinetr
patient
around
posttranspl
tli
combin
monoclon
antibodi
atg
donorspecif
blood
transfus
seem
effect
rat
heart
allograft
model
basi
result
efficaci
tli
evalu
heart
transplant
patient
therapyresist
earli
vascular
reject
result
signific
reduct
reject
recurr
effect
maintain
least
year
meantim
favor
result
confirm
sever
group
also
tlitreat
patient
develop
less
coronari
atherosclerosi
match
control
despit
multipl
reject
episod
scandl
et
al
report
use
tli
induc
toler
set
combin
kidneyhematopoiet
stem
cell
transplant
hlamatch
donorrecipi
pair
patient
receiv
condit
regimen
dose
tli
cgi
five
dose
rabbit
atg
mmf
month
cyclosporin
least
month
donor
hematopoiet
stem
cell
inject
intraven
day
outpati
infus
center
major
patient
abl
discontinu
antireject
medic
patient
excel
graft
function
last
observ
point
reason
continu
immunosuppress
therapi
recurr
focal
segment
glomerulosclerosi
one
four
patient
reject
episod
taper
cyclosporin
three
patient
conclus
tli
shown
safe
immunosuppress
regimen
abandon
clinic
practic
organiz
reason
except
treatment
therapyresist
reject
heart
heartlung
transplant
howev
abil
induc
toler
combin
atg
hematopoiet
stem
cell
transplantationmight
renew
interest
treatment
modal
date
evid
radiationrel
late
effect
document
tli
extracorpor
photopheresi
techniqu
leukocyt
remov
patient
leukopheresi
expos
ultraviolet
light
develop
immunoregulatori
treatment
erythroderm
cutan
tcell
lymphoma
subsequ
procedur
shown
safe
altern
treatment
variou
human
immun
autoimmun
diseas
furthermor
rat
monkey
regimen
shown
result
extend
skin
allograft
cardiac
allograft
xenograft
surviv
differ
mechan
shown
contribut
immunomodulatori
effect
photopheresi
select
inhibit
effector
cell
induct
high
rate
apoptosi
increas
capac
phagocytos
apoptot
cell
result
induct
anticlonotyp
immun
respons
shift
toward
immun
activ
induct
regulatori
cell
clinic
transplant
photopheresi
appli
therapeut
prophylact
option
appli
treatment
recurr
resist
acut
reject
renal
transplant
patient
number
patient
includ
studi
limit
prospect
random
trial
need
safeti
efficaci
photopheresi
prevent
acut
reject
cardiac
allograft
evalu
primari
cardiac
allograft
recipi
randomli
assign
standard
tripledrug
immunosuppress
therapi
cyclosporin
azathioprin
prednison
alon
conjunct
photopheresi
session
perform
first
month
transplant
month
followup
photopheresistr
patient
develop
significantli
fewer
multipl
reject
signific
differ
rate
type
infect
although
signific
effect
graft
surviv
rate
month
studi
indic
photopheresi
may
effect
new
immunosuppress
regimen
transplant
recipi
patient
refractori
bronchiol
obliteran
lung
transplant
photopheresi
result
stabil
graft
function
andor
patient
histolog
revers
reject
splenectomi
pretranspl
splenectomi
recipi
transplant
first
propos
starzl
et
al
mean
improv
graft
surviv
although
splenectomi
standard
procedur
patient
develop
hypersplen
azathioprineassoci
leukopenia
evid
role
splenectomi
enhanc
graft
surviv
controversi
larg
prospect
random
trial
minneapoli
show
splenectomi
improv
graft
surviv
significantli
longerterm
followup
show
loss
benefici
effect
increas
infectionrel
mortal
sever
singlecent
studi
shown
alarm
risk
sepsi
death
nullifi
earli
benefit
splenectomi
graft
surviv
multicent
analysi
south
eastern
organ
procur
foundat
confirm
modest
improv
graft
surviv
splenectomi
relentless
increas
patient
mortal
splenectomi
place
prepar
recipi
receiv
aboincompat
graft
practic
like
becom
wide
employ
live
relat
donor
transplant
aboincompat
otherwis
suitabl
donor
avail
donor
alexandr
et
al
report
seri
aboincompat
live
donor
transplant
recipi
prepar
plasmapheresi
donorspecif
platelet
transfus
splenectomi
although
author
believ
need
plasmapheresi
donorspecif
platelet
transfus
reevalu
splenectomi
thought
import
sinc
recipi
splenectomi
lost
graft
acut
vascular
reject
contrast
undergo
splenectomi
smallscal
success
experi
postsplenectomi
aboincompat
live
donor
kidney
transplant
also
report
ishikawa
et
al
japan
set
aboincompat
kidney
transplant
antigenspecif
immunoadsorpt
rituximab
bortezomib
treatment
develop
altern
plasmapheresi
splenectomi
reduc
indic
splenectomi
organ
transplant
plasmapheresi
plasmapheresi
appli
three
set
relat
organ
transplant
first
treatment
steroidresist
acut
reject
morpholog
predominantli
vascular
consid
antibodymedi
rather
cellmedi
although
initi
report
suggest
benefici
effect
control
trial
unconvinc
nojima
et
al
report
success
treatment
antibodymedi
acut
renal
allograft
reject
combin
plasmapheresi
second
set
prepar
recipi
aboincompat
live
donor
kidney
refer
earlier
although
brynger
et
al
report
success
aboincompat
graft
without
prior
plasmapheresi
recipi
third
set
plasmapheresi
use
attempt
reduc
titer
broad
reactiv
hla
antibodi
highli
sensit
candid
transplant
dialysi
patient
combin
cyclophosphamiderituximab
therapi
prevent
reappear
antibodi
encourag
earli
result
approach
report
although
associ
consider
morbid
immunoabsorpt
appli
altern
plasmapheresi
found
equal
effici
method
studi
approach
highli
sensit
candid
transplant
recipi
continu
